LEPR and obesity due to melanocortin 4 receptor deficiency: Initially, it was FDA approved in November 2020 for chronic weight management in adults and pediatric patients aged 6 years of age and older with obesity due to POMC, PCSK1, and LEPR deficiency, and later in June 2022 for Bardet–Biedl syndrome (BBS), all rare genetic disorders that lead to severe early-onset obesity.